Costs of care for irritable bowel syndrome patients in a health maintenance organization.
about
Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infectionClinical practice. Irritable bowel syndromeRisk of inflammatory bowel disease following a diagnosis of irritable bowel syndromeThe need for knowledge translation in chronic pain.Estimating the burden of irritable bowel syndrome: analysis of a nationwide korean database.Pain symptoms and stooling patterns do not drive diagnostic costs for children with functional abdominal pain and irritable bowel syndrome in primary or tertiary careTrauma history and risk of the irritable bowel syndrome in women veterans.Predictors of patient-assessed illness severity in irritable bowel syndrome.Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.A prospective 1-year follow-up study in patients with functional or organic dyspepsia: changes in gastrointestinal symptoms, mental distress and fear of serious illness.Somatic complaints in childhood functional abdominal pain are associated with functional gastrointestinal disorders in adolescence and adulthoodTreating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics.Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness.Lubiprostone in constipation: clinical evidence and place in therapy.Novel therapies in the treatment of irritable bowel syndrome.Systematic review: the economic impact of irritable bowel syndrome.Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review.Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidenceChange in Quality of Life for Patients with Irritable Bowel Syndrome following Referral to a Gastroenterologist: A Cohort StudyComparison of medical costs generated by IBS patients in primary and secondary care in the NetherlandsBiliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study.An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium.Review article: epidemiology and quality of life in functional gastrointestinal disorders.Protease-activated receptors: potential therapeutic targets in irritable bowel syndrome?The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndromeFrom the bench to the 'crib'-side: implications of scientific advances to paediatric neurogastroenterology and motility.Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.Serotonin receptor modulators in the treatment of irritable bowel syndrome.Negative aspects of close relationships are more strongly associated than supportive personal relationships with illness burden of irritable bowel syndromePsychosocial predictors of self-reported fatigue in patients with moderate to severe irritable bowel syndrome.Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.Functional gastrointestinal disorder is associated with increased non-gastrointestinal healthcare consumption in the general populationFunctional gastrointestinal disorders as a public health problem.Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome.Fear of GI symptoms has an important impact on quality of life in patients with moderate-to-severe IBS.Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.Asimadoline in the treatment of irritable bowel syndrome.Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.Mid-level providers in gastroenterology.
P2860
Q21198942-55843C48-45FA-4C00-8AA8-2FE1620C7638Q24602718-C771EEB7-2CC3-45C0-BF5F-2E0839689E84Q31062841-47E4475C-697E-44D6-917D-976600F64889Q33562393-40337762-956B-4D09-A952-B1D0D757FE5CQ33586874-EF5C5FA4-5821-4C39-BBE1-396C1364132BQ33651581-7B84C45F-73E7-45E6-8D00-8864689A7175Q34005405-1D8E1539-B494-49D6-A43D-6E1FBF81296DQ34170665-F28BEFE6-D72B-49C3-BFF6-0ABC571C837CQ34179472-F87636FD-D767-4083-8BC8-A51BFDC2DF00Q34570680-75A271BF-5F88-44C5-B4F6-1526929D348BQ34580702-48EF10A8-A6DE-493C-80B5-FD5C2897B4B0Q34603139-AC525BF7-1E08-4F13-8051-2DF66FF86175Q34627613-0A4A6469-5025-49C8-98C5-4124BF233C6AQ35091370-04B7A3A2-6108-482B-91EB-2D7117A4E759Q35094684-85C90A7E-2ECC-4454-98B9-3143EC64191FQ35544074-D60821DE-AB50-46FE-9A66-E436B4448973Q35752958-AF0B6AF2-3875-4CAB-BB51-AE91A623B6F6Q35768888-34E7B1D6-07C9-4F39-AD3F-7822F1BA4571Q35797307-9D744BB5-24C7-4613-8904-768A106AB7BCQ35854169-FB241D22-4847-41CD-B21A-2B0C7417A72EQ35910817-CDAFD1E7-26C9-4940-93E3-D4321ED05C5AQ35917169-E7AC87CA-89D4-4E5E-909C-0381317CC60AQ35936950-DCF14140-6D8C-43C8-B622-D1AD2F21F734Q36268344-6A655C84-1ECD-46BA-BFB6-FD75B621A308Q36309936-41A3739F-5522-4FE8-9019-0429E4032051Q36428527-4BC72971-DBB0-40ED-8E09-E94E63467743Q36573807-24965C4D-6EAF-4AD9-B935-EEB44215DB2DQ36822923-6655FAC7-3F23-47FB-BA56-FA069930CEE6Q36904034-8FA1B2E4-962D-45E5-A36A-592387A05B62Q37090536-EB8E0904-7999-45ED-903C-3F152A04A0CAQ37099359-5291753F-F619-489A-B3FB-402FAB83841FQ37134240-061FE289-971F-4344-877A-56828336A799Q37134568-DA120141-1026-4210-AD08-A5827000D7E9Q37189148-1D12D081-789F-49AE-868A-1749DA573ED9Q37415508-46CF3552-9484-454E-9BFF-E9964343FF0DQ37671189-91178044-8BEC-41CF-A425-DBD603174123Q37784531-1DCBD167-71D6-42AD-A480-FCD0EAECF565Q37869371-AB19541D-76CC-4BF0-82CD-F5DE5875F63FQ39396013-4087534F-1CB2-4236-9BD9-7A86CE96E778Q39902717-4BDD4D86-F5D2-4604-B581-FB7B76AEA3DE
P2860
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@ast
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@en
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@nl
type
label
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@ast
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@en
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@nl
prefLabel
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@ast
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@en
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@nl
P2093
P2860
P1476
Costs of care for irritable bowel syndrome patients in a health maintenance organization.
@en
P2093
Barghout V
Jhingran P
Saunders K
Von Korff M
Whitehead WE
P2860
P304
P356
10.1111/J.1572-0241.2001.05258.X
P407
P577
2001-11-01T00:00:00Z